- Aidsmap: Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
Long-acting cabotegravir and rilpivirine injections may be a feasible option for people who struggle to stay engaged with traditional HIV care and have been unable to maintain viral suppression on oral antiretroviral therapy, according to a report presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) in Seattle.
People with HIV who switched from bictegravir to injectable cabotegravir and rilpivirine rarely experienced substantial changes in body weight, Dr Darrell Tan of St Michael’s Hospital, Toronto, reported at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) in Seattle.
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.